COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Jcovden (previously COVID-19 Vaccine Janssen)
|
| Active substance |
adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)
|
| Therapeutic area (MeSH) |
COVID-19 virus infection
|
| Procedure number |
EMEA/H/C/005737
|
| Regulatory outcome |
Variation
|
| DHPC type |
Safety signal
|
| Human ATC code |
J07BX03
|
| Dissemination date |
19/07/2021
|